Form 4: Revolution Medicines GC Sells Shares Under 10b5-1 Plan

Revolution Medicines' General Counsel, Jeff Cislini, sold 908 shares of common stock for $115.6 per share under a pre-arranged 10b5-1 plan.

Summary

• Jeff Cislini, the General Counsel of Revolution Medicines, Inc. (RVMD), reported the disposition of 908 shares of common stock.
• The transaction occurred on January 21, 2026, with shares sold at a price of $115.6 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Cislini on March 13, 2025.
• Following this transaction, Mr. Cislini beneficially owns 46,976 shares of Revolution Medicines common stock, which includes 38,769 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction under a pre-arranged 10b5-1 plan, which is a neutral event in terms of company performance or outlook. The transaction size is not significant enough to indicate strong positive or negative sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction under a pre-arranged trading plan, which is a common practice for corporate executives to manage their equity holdings in compliance with insider trading regulations. It does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• The sale of 908 shares by the General Counsel is a relatively small transaction and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Revolution Medicines, RVMD, Jeff Cislini, insider transaction, Form 4, stock sale, 10b5-1 plan, General Counsel